VivoSim Labs Prices Best-Efforts Public Offering

VivoSim Labs ( (VIVS) ) has shared an update.

On March 31, 2026, VivoSim Labs priced a best-efforts public offering of up to roughly $4 million in common stock or pre-funded warrants, paired with common warrants, structured in two tranches. At the initial closing on April 1, 2026, the company raised approximately $3 million in gross proceeds through the sale of 286,557 common shares, 2,345,022 pre-funded warrants, and 3,947,369 common warrants, generating about $2.5 million in net proceeds after fees.

The common warrants, exercisable at $1.71 per share and featuring anti-dilution protection and cashless exercise features, could substantially increase VivoSim’s share count upon exercise, while a potential second tranche of up to $1 million remains contingent on share price and trading volume thresholds 30 days after the initial closing. Net proceeds are earmarked for working capital and general corporate purposes, including R&D, regulatory affairs and potential technology acquisitions, underscoring the company’s effort to strengthen its balance sheet and advance its NAM-based preclinical safety services in a market steadily shifting toward non-animal testing.

More about VivoSim Labs

VivoSim Labs, Inc. is a San Diego-based pharmaceutical and biotechnology services company specializing in next-generation New Approach Methodologies (NAMs) for preclinical safety testing. It provides drug developers with liver and intestinal toxicology insights using three-dimensional human tissue models, positioning itself to benefit from the U.S. FDA’s April 10, 2025 move to refine animal testing requirements in favor of non-animal NAM methods.

The company’s focus on 3D human liver and intestine models targets partners seeking more predictive, human-relevant safety data. VivoSim’s offerings align with a broader industry shift away from animal studies, potentially enhancing its appeal to biopharma clients adapting to evolving regulatory expectations.

Average Trading Volume: 1,643,716

Technical Sentiment Signal: Strong Sell

Current Market Cap: $4.41M

For an in-depth examination of VIVS stock, go to TipRanks’ Overview page.